Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market Size
Market Size in USD Bn
CAGR5.1%
| Study Period | 2025-2032 |
| Base Year of Estimation | 2024 |
| CAGR | 5.1% |
| Market Concentration | Medium |
| Major Players | GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceuticals and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market Analysis
The chronic obstructive pulmonary disease (COPD) diagnosis market is estimated to be valued at USD 2.29 billion in 2025 and is expected to reach USD 3.24 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032. Market growth can be attributed to the growing geriatric population which are more susceptible to COPD, increasing pollution levels leading to higher incidence of COPD, and availability of more accurate diagnostic tests to detect early stages of COPD.